Resistance to chemotherapy and radiation is a big obstacle for patients with glioblastoma multiforme (GBM) Therefore, it is critical to understand mechanisms responsible for chemo-radioresistance these patients. Our recent findings led us to hypothesize that the histone methyltransferase (HMT) MMSET is a contributor to chemoradioreslstance. MMSET (also called WHSC1, NSD2) has been shown to methylate histone H4 Lys20 (H4K20), H3 Lys27 (H3K27) and H3 Lys36 (H3K36). Besides several reports linking it to transcriptional regulation, the cellular function of MMSET remains obscure. We found that MMSET participates in the ATM-MDC1-53BP1 pathway during the DNA damage response. Specifically, MMSET accumulates at sites of DNA damage. Correlating with this, H4K20 methylation, which is required for 53BP1 recruitment [1], also increases at the sites of DNA damage. Downregulation of MMSET decreases H4K20 methylation and abolishes the accumulation of 53BP1 to the sites of DNA damage. These results suggest that MMSET functions as an upstream regulator of 53BP1 through its HMT activity. In support of its role in DNA damage responses, MMSET affects cellular sensitivity to temozolomide (TMZ) and radiation (RT). Finally, we found that MMSET is overexpressed in a subset of glioblastoma lines, and overexpression of MMSET is associated with resistance to temozolomide (TMZ) and radiation (RT). Based on these preliminary findings, we hypothesize that MMSET regulates 53BP1 and the TMZ/RT response, and that misregulation of MMSET could affect GBM sensitivity to chemo-radiotherapy (Figure 1). To further examine this hypothesis, we propose the following Specific Aims: 1. Structure-function analysis of MMSET in the DNA damage response;2. Investigate the role of MMSET in TMZ/RT response using mouse models;3. Examine the expression of MMSET in GBM patients and its correlation with TMZ/RT response. These studies will reveal a novel role of MMSET in cellular response to genotoxic stress. Furthermore, the planned translational studies will define whether MMSET is an important modulator of treatment response for glioblastoma patients, which would provide key insight into why at least some patients with a favorable MGMT methylation status fare poorly with chemo-radiotherapy.

Public Health Relevance

(See insfructions): Overcoming GBM's resistance to chemotherapy and radiation is critical to overcome this disease, however, one needs to first understand the mechanism underlying the resistance. This proposal will test whether overexpression of MMSET contributes to the chemo-radioresistance of GBM. This will ultimately lead to the identification of a novel drug target and biomarker for GBM therapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA108961-09
Application #
8729254
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
9
Fiscal Year
2014
Total Cost
$133,829
Indirect Cost
$48,706
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Geekiyanage, Hirosha; Galanis, Evanthia (2016) MiR-31 and miR-128 regulates poliovirus receptor-related 4 mediated measles virus infectivity in tumors. Mol Oncol 10:1387-1403
Rajani, Karishma; Parrish, Christopher; Kottke, Timothy et al. (2016) Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses. Mol Ther 24:166-74
Ma, Yufang; Tang, Nan; Thompson, Reid C et al. (2016) InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma. Clin Cancer Res 22:1767-76
Hardcastle, Jayson; Mills, Lisa; Malo, Courtney S et al. (2016) Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment. Neuro Oncol :
Vaubel, Rachael A; Chen, Selby G; Raleigh, David R et al. (2016) Meningiomas With Rhabdoid Features Lacking Other Histologic Features of Malignancy: A Study of 44 Cases and Review of the Literature. J Neuropathol Exp Neurol 75:44-52
Kurokawa, C; Geekiyanage, H; Allen, C et al. (2016) Alisertib demonstrates significant antitumor activity in bevacizumab resistant, patient derived orthotopic models of glioblastoma. J Neurooncol :
Zhang, Haoxing; Liu, Hailong; Chen, Yali et al. (2016) A cell cycle-dependent BRCA1-UHRF1 cascade regulates DNA double-strand break repair pathway choice. Nat Commun 7:10201
Lescarbeau, Rebecca S; Lei, Liang; Bakken, Katrina K et al. (2016) Quantitative Phosphoproteomics Reveals Wee1 Kinase as a Therapeutic Target in a Model of Proneural Glioblastoma. Mol Cancer Ther 15:1332-43
Kitange, Gaspar J; Mladek, Ann C; Schroeder, Mark A et al. (2016) Retinoblastoma Binding Protein 4 Modulates Temozolomide Sensitivity in Glioblastoma by Regulating DNA Repair Proteins. Cell Rep 14:2587-98
Cockle, Julia V; Rajani, Karishma; Zaidi, Shane et al. (2016) Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling. Neuro Oncol 18:518-27

Showing the most recent 10 out of 220 publications